WO2024208244 - ANTI-IGF1R ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/208244
Publication Date
10.10.2024
International Application No.
PCT/CN2024/085734
International Filing Date
03.04.2024
Title **
[English]
ANTI-IGF1R ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-IGF1R ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
No. 12, Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD.
No. 9, Huiou Road
Nanjing Economic and Technological Development Zone
Nanjing, Jiangsu 210038, CN
Inventors
AN, Wenqian
No. 12, Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
CAO, Wenpeng
No. 12, Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
LI, Rifei
No. 12, Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
WANG, Zilin
No. 12, Baoshen South Street
Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
Priority Data
PCT/CN2023/086082
04.04.2023
CN
PCT/CN2023/115246
28.08.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2566 | |
| EPO | Filing, Examination | 24496 | |
| Japan | Filing | 538 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 18435 |
Total: 46643 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments,and the uses thereof.[French]
L'invention concerne des anticorps anti-IGF1R (récepteur du facteur de croissance 1 de type insuline), des fragments de liaison à l'antigène et leurs utilisations.